CJC-1295: DAC vs No-DAC Explained
Sleep, recovery and the DAC question
People consider CJC-1295 for better sleep, training recovery and changes in body composition. The first distinction is DAC versus no DAC: they create different exposure patterns.
The long-acting DAC form has human hormone-response studies. Those results do not establish better recovery or muscle growth, and they cannot simply be applied to no-DAC products.
The difference in the name
With DAC 5.8–8.1 days
Estimated drug half-life in healthy-adult research.
No DAC
Usually modified GRF(1–29), without the long-acting attachment. The DAC study does not establish its timing.
Reported doses: DAC and no DAC side by side
These are named supplier examples, not established safe or effective regimens. Each row keeps its source’s amount, route and duration together.
| Form and source | Amount per administration | Frequency and duration |
|---|---|---|
| DAC: Exoma supplier guide | 1–2 mg under the skin | Once weekly; 8–12 weeks, followed by a 4-week break in that guide |
| No DAC: CXPeptides sleep/recovery example | 100 mcg under the skin | Once daily for 8 weeks |
Both supplier descriptions were rechecked October 12, 2026. Their efficacy and safety claims are not adopted. 1 mg = 1,000 mcg; neither figure is a syringe marking. The DAC and no-DAC profiles provide the fuller product context.
Why there are two versions
DAC means Drug Affinity Complex. CJC-1295 is related to growth-hormone-releasing hormone (GHRH), which signals the pituitary to release growth hormone. The long-acting research molecule attaches to albumin, a circulating blood protein. “No DAC” commonly refers to modified GRF(1–29), without that albumin-binding extension; naming on commercial listings can be inconsistent.
What the name should tell you
| Compare | CJC-1295 with DAC | Products called no DAC |
|---|---|---|
| Key design feature | Albumin-binding extension | No albumin-binding DAC extension |
| Main human evidence discussed here | Healthy-adult GH, IGF-1 and exposure studies | The DAC trial is not a study of this formulation |
| Half-life claim | Estimated at 5.8–8.1 days in the trial | A quoted 30 minutes needs a source for the exact molecule and route |
| What is not established | A bodybuilding or recovery program | A superior or safer daily pulse schedule |
What the human studies found
The 2006 Teichman study comprised two short randomized, placebo-controlled trials in healthy adults. A single subcutaneous administration increased mean GH for at least six days and IGF-1 for roughly nine to eleven days; the estimated CJC-1295 half-life was 5.8–8.1 days. Repeated administration showed a cumulative effect. These were hormonal and pharmacokinetic outcomes, not evidence of better injury recovery, fat loss or lifespan. Original healthy-adult study.
A separate study makes an important distinction: GH pulsatility persisted during CJC-1295 exposure, even though trough and mean GH increased. Long-acting drug exposure does not mean growth hormone becomes a perfectly flat line. Ionescu and Frohman.
Pharmacokinetics comparison
Three curves can be confused: the concentration of CJC-1295, the pituitary’s GH release, and the downstream IGF-1 response. They are not the same measurement. A CJC-1295 plot cannot be read as a GH blood test or used to prove that a particular injection time captures a natural pulse.
The original human data support prolonged exposure to the DAC molecule. They do not validate the exact half-life, bioavailability or “back to baseline within an hour” claims often attached to modified GRF. An assumed short curve can illustrate a mathematical contrast, provided it remains labeled as such.
Stacking strategy
GHRH and ghrelin-receptor agents such as ipamorelin act through different signaling routes. That supplies a hypothesis for combination research; it does not establish that a commercial blend improves outcomes, preserves a “more natural” pattern, or has a known chemical compatibility in one syringe.
Do not treat a two-ingredient vial as a clinical trial. Its component amounts, product quality, route and stability are separate questions from whether both ingredients can influence GH.
Research dosing context
The published CJC-1295 trials used controlled, weight-based research dosing. Converting those experiments into a universal milligram-per-week program would require evidence about the intended condition, long-term safety and product equivalence. The clinical question is whether an appropriate diagnosis and monitoring plan support treatment—not which generic cycle is most convenient.
Side effects
FDA identifies limited clinical data and safety concerns for CJC-1295, including reports of increased heart rate and systemic vasodilatory reactions, as well as impurity and immune-response concerns. A short trial reporting no serious adverse events does not cancel those later concerns. FDA safety information.
Frequently asked questions
Is DAC better than no DAC? Longer exposure is a design feature, not a measure of clinical superiority. No head-to-head result reviewed here establishes a preferred recovery or anti-aging treatment.
Can I mix it with ipamorelin? The cited studies do not establish a mixing recipe or storage stability for that combination.
Does it need refrigeration? Storage is formulation-specific. A generic peptide name cannot establish the stability of a prepared solution.
Is it prohibited in sport? CJC-1295 is named among prohibited GH-releasing factors in WADA’s 2026 list.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.